** Shares of drug developer Pliant Therapeutics PLRX.O fall 65.5% to $2.72 in extended trading
** Company says a mid-stage trial testing experimental drug bexotegrast in patients with idiopathic pulmonary fibrosis has been paused
** Says enrollment and dosing has been paused while a Data Safety Monitoring Board (DSMB) reviews its trial data
** A DSMB refers to an independent group of experts that reviews clinical trial data to ensure the safety of participants and the validity of the trial
** Idiopathic pulmonary fibrosis is a chronic lung disease that causes scarring and stiffening of the lung tissue
** Up to last close, stock down 40.9% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。